United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 7 minute read Pharma Industry News Can Avacta’s £16m fundraise extend its oncology momentum after 91% disease control rate? Avacta raises £16m to extend clinical runway into 2026 and reports 91% disease control in cancer trial. See why investors are watching AVCT closely. bySrinathOctober 20, 2025